Cure8 research brief
Many people with IBD worry that IVF/ART could trigger disease flares or affect pregnancy success. This study reports low short-term flare rates after ART and pregnancy outcomes similar to general expectations, which may reassure patients and clinicians planning fertility care alongside IBD management.
People with Crohn’s disease or ulcerative colitis considering IVF/ART; patients on biologic therapy; fertility and IBD clinicians; researchers in IBD and reproduction.
This retrospective single-center study reviewed 149 assisted reproductive technology (ART) encounters in 49 women with IBD (mostly Crohn’s disease or ulcerative colitis). The authors measured disease activity before and after ART using medication changes, steroid starts, biomarkers, and IBD-related healthcare use.
Overall flare rate within 6 months of ART was low (3.4% of encounters), with flares occurring after embryo transfer during established pregnancy rather than around oocyte retrieval. Rates of new steroid use, IBD hospitalization, and medication dose escalation were also low.
Live birth rate per embryo transfer was reported as 42.9% and biochemical pregnancy 63.5%. The study suggests that, within this cohort and with multidisciplinary care, ART including oocyte retrieval and embryo transfer was associated with a low short-term risk of IBD exacerbation and reasonable pregnancy outcomes.
The findings are based on retrospective chart review and reflect one center’s experience. If you are considering ART, discuss timing, ongoing IBD medications, and monitoring plans with both your fertility specialist and IBD team so medication management and flare surveillance are coordinated.
Retrospective single-center design, small sample size, and short (6-month) flare window limit generalizability. Management was multidisciplinary; outcomes may differ where coordinated care is not available.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
